193 Stewardship Role in the Periprocedural Management of Patients with Hemophilia A Before and After Introduction of Emicizumab
Introduction: Emicizumab, approved for bleed prevention in congenital hemophilia A, was added to formulary in 2019 with stewardship program oversight. The stewardship program evaluated the perioperative factor management of hemophilia A patients before and after emicizumab adoption.
Authors
- Katelyn W. Sylvester (ORCID: https://orcid.org/0000-0001-9208-2354)
- Dareen M. Kanaan (ORCID: https://orcid.org/0000-0003-4942-6689)
- Jean M. Connors (ORCID: https://orcid.org/0000-0001-6445-582X)
- Nathan T. Connell (ORCID: https://orcid.org/0000-0003-4100-7826)
- Daniel Cartagena-Sergenian
Institutions
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.102765
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00